Roivant Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROIV research report →
Range $41 – $62
Price Chart
About the company
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia.
- CEO
- Matthew Gline
- IPO
- 2020
- Employees
- 721
- HQ
- London, GL, GB
AI snapshot
Six angles, distilled from the data.
ROIV remains in a strong multi-month uptrend, trading well above its 200-day moving average of 32.22 and its 50-day of 37.20. The stock is still near the top of its 52-week range at 42.50, so the regime favors momentum, though it is no longer in an early-base setup.
Street sentiment is constructive: 14 Buy ratings, 2 Holds, and no Sells, with a consensus Buy and a target range of 41 to 62. The average target sits around 49.50, above the recent close, and recent actions have mostly been reiterations or target raises, with only one downgrade to Peer Perform.
The earnings pattern is mixed but workable: ROIV has beaten EPS in 5 of the last 8 quarters, including a 42.3% beat in the latest report. Next-year EPS estimates are still negative at -1.1589, so shareholders should watch for continued loss narrowing and whether revenue growth can keep offsetting development spend.
No discretionary insider buying or selling stands out. Recent filings are dominated by large J-Other and F-InKind transactions from the CEO, President & Vant Chair, and President/CIO, which read more like automatic or non-open-market activity than conviction trading.
The balance sheet is a clear strength, with $4.29 billion in cash against $107.44 million of debt and net cash of $4.18 billion. Profitability remains weak, with operating margin at -32.26% and ROE at -8.54%, but revenue still grew 21.356% year over year.
ROIV screens like a premium-growth biotech rather than a value name, supported by a large cash position and analyst support. The setup favors a higher-multiple peer group, but the current valuation still reflects losses and execution risk more than established profitability.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.01B
- P/E
- -81.17
- Fwd P/E
- 38.97
- PEG
- 0.72
- P/S
- 687.14
- P/B
- 7.00
- EV/EBITDA
- -90.59
- Div Yield
- 0.00%
- Gross Margin
- 88.68%
- Op Margin
- -1358.15%
- Net Margin
- -838.19%
- ROE
- -8.08%
- ROIC
- -11.85%
Latest fiscal year · YoY change
- Revenue
- $8.26M-71.6%
- Gross Profit
- $6.97M-75.2%
- Op Income
- $-515,068,000
- Net Income
- $-299,771,000-74.3%
- EPS
- $-0.43-79.2%
- OCF Growth
- +10.6%
- FCF Growth
- +10.1%
- 52W High
- $42.50
- 52W Low
- $19.96
- 50D MA
- $37.22
- 200D MA
- $32.65
- Beta
- 1.20
- RSI (14)
- 53
- Avg Volume
- 8.16M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Roivant delivered a strong quarter highlighted by a fast start for LISRAYA, encouraging new RA data for IMVT-1402, and continued momentum across its broader pipeline.· November 9, 2026
- LISRAYA generated $31 million of net revenue in its first ~5 weeks on the market, with hundreds of patients on paid drug at quarter-end and many hundreds now.
- IMVT-1402’s Period 2 RA study hit its primary endpoint: 600 mg maintained ACR20 responses better than placebo, while 300 mg looked similar to placebo, reinforcing the importance of deeper IgG suppression.
- Safety for IMVT-1402 remained consistent with prior updates, with no new safety signals reported.
- Roivant reiterated strong data for brepo in NIU and mosliciguat in PH-ILD, and said both programs remain important growth pillars.
- Management signaled it is probably not going forward with Sjogren’s, citing evolving field data and competitors’ setbacks, while FDA discussions on the RA program are still ongoing.
Roivant reported net revenue of $31 million from LISRAYA in the quarter, reflecting roughly 5 weeks on the market after an August approval. The company posted a loss from continuing operations of $153 million, or $133 million on a non-GAAP basis, and ended the quarter with $4.2 billion of cash. Management said the quarter included a meaningful amount of undispensed drug at specialty pharmacies, which likely helped the September quarter and could create a modest headwind in the December quarter. No formal next-quarter or full-year financial guidance was given; instead, management pointed to continued commercial launch monitoring, ongoing FDA discussions for IMVT-1402, an NIU sNDA filing, and multiple 2027 data readouts.
Matt Gline said the quarter was transformational, driven by LISRAYA’s launch and encouraging clinical progress across multiple programs. He emphasized that the early commercial response in dermatomyositis reflects substantial unmet need, broad prescriber interest, and workable payer dynamics so far. On R&D, he framed the RA, NIU, and PH-ILD updates as validation of Roivant’s approach and said the company has a busy 2027 ahead, with more trials and indications potentially coming.
The call did not include a separate CFO speech, but management provided the main financial update: a $153 million loss from continuing operations, $133 million non-GAAP, and $4.2 billion in cash as of 9/30, helped in part by receipts from Moderna litigation over the summer. Matt Gline also noted that Roivant repurchased about $280 million of stock, or about 9.4 million shares, during the 6 months ended 9/30. He described expenses as relatively consistent with expectations. Capital allocation remains active through buybacks, while the cash balance gives flexibility to fund the pipeline.
Analysts focused heavily on LISRAYA launch dynamics, asking about paid prescriptions, inventory stocking, payer coverage, and where demand is coming from. Management said there were many hundreds of patients on paid drug, access has been straightforward so far, and some pharmacy inventory built in the quarter should largely wash out by next year. On IMVT-1402, questions centered on dose-response, FDA path, and study design; management said 600 mg outperformed 300 mg, FDA discussions are ongoing, and a straightforward RCT now looks more likely than a randomized-withdrawal design. Management also said Sjogren’s is unlikely to move forward, citing competitor failures and a weaker field outlook.
The call showed real commercial traction for LISRAYA right out of the gate, with strong physician enthusiasm and early payer coverage supporting uptake. Roivant also disclosed unexpectedly strong RA maintenance data for IMVT-1402 at the higher dose, which management believes strengthens the case for deeper IgG suppression and a meaningful late-line RA opportunity. Beyond that, brepo and mosliciguat continue to generate high-profile clinical momentum, giving the company multiple shots at value creation.
The LISRAYA launch is still very early, and management repeatedly warned that inventory stocking and short launch timing make the first-quarter revenue number hard to extrapolate. For IMVT-1402, FDA alignment is still pending, so there is uncertainty around trial design, endpoints, and whether one Phase III will be enough. Management also indicated Sjogren’s is probably not moving forward, and the company acknowledged that payer policies for LISRAYA could become more restrictive over time.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.0%
- Shares Outstanding
- 724.56M
- Float Shares
- 572.71M
of shares held by institutions
519 13F filers
Buy/sell ratio 0.09. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ROIV, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 85.58M | ▲ 4.56M |
| Blackrock, Inc. | 61.88M | ▲ 13.64M |
| Vanguard Group Inc | 42.06M | ▲ 3.25M |
| Morgan Stanley | 38.60M | ▼ 3.99M |
| Qvt Financial LP | 23.72M | 0 |
| Vanguard Capital Management LLC | 23.13M | ▲ 1.00M |
| State Street Corp | 22.40M | ▲ 4.60M |
| Farallon Capital Management, L.L.C. | 21.75M | ▲ 7.44M |
| Vanguard Portfolio Management LLC | 21.66M | ▲ 15.92K |
| Ubs Group AG | 13.93M | ▼ 3.54M |
| Geode Capital Management, LLC | 12.52M | ▲ 847.24K |
| Jennison Associates LLC | 12.07M | ▲ 7.59M |
Held by 739 ETFs
Biggest fund positions in ROIV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Hammerbacher Jeffrey Evan | other | 0 |
| Nov 16, 26 | MANCHESTER KEITH S | sell | 79,461 |
| Nov 16, 26 | MANCHESTER KEITH S | sell | 18,927 |
| Nov 17, 26 | MANCHESTER KEITH S | other | 15,969 |
| Nov 17, 26 | MANCHESTER KEITH S | sell | 75,716 |
| Nov 17, 26 | MANCHESTER KEITH S | other | 2,635,169 |
| Nov 17, 26 | MANCHESTER KEITH S | sell | 798 |
| Nov 16, 26 | MANCHESTER KEITH S | sell | 550,280 |
| Nov 16, 26 | MANCHESTER KEITH S | sell | 131,073 |
| Nov 17, 26 | MANCHESTER KEITH S | other | 385,620 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ROIV coverage
Recent articles, reports, and earnings notes.

Roivant Sciences (ROIV): Cash-Rich Biotech With Launch Catalysts
Roivant Sciences is a cash-rich biotech platform with a near-term brepocitinib launch and several late-stage catalysts, but valuation already reflects meaningful execution risk. The stock is a Hold as investors wait for commercial proof and clinical readouts.

Roivant Sciences Ltd. (ROIV) jumps 20% on PH-ILD data
Roivant Sciences Ltd. (ROIV) jumps after reporting positive Phase 2 data for mosliciguat in PH-ILD. The readout boosted investor sentiment as the company advanced the program into Phase 3, though the stock now trades above its consensus target and still faces clinical and commercial execution risk.

Attovia Therapeutics IPO: What Investors Need to Know
Attovia Therapeutics, Inc. (NASDAQ: ATTO) is expected to list on 2026-08-05, but the price range has not been disclosed. The company plans to offer 17,000,000 shares. The setup is attractive if investors want early-stage immunology exposure, but the story still depends on clinical execution and funding discipline.
Want a deeper read on ROIV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
zacks.com · Nov 20
Wall Street Analysts Think Montes Archimedes Acquisition (ROIV) Could Surge 29.62%: Read This Before Placing a Bet
zacks.com · Nov 20
126,491 Shares in Roivant Sciences Ltd. $ROIV Bought by Edgestream Partners L.P.
defenseworld.net · Nov 20
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
seekingalpha.com · Nov 11
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
globenewswire.com · Nov 10
Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position
defenseworld.net · Nov 10
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice